Company: INSP
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001609550-25-000020
Chunk: 6

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-05-05
Form: 10-Q
Item: Part II, Item 2
Chunk 6
---
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

Unregistered Sales of Equity Securities

None.

Share Repurchases

The following table presents information with respect to the repurchase of our common stock during the three months ended March 31, 2025:

PeriodTotal Number of Shares Purchased(1)Average Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Program(1)Approximate Dollar Value of Shares that May Yet Be Repurchased Under the Program (in thousands)January 1, 2025 - January 31, 2025—$— —$75,000 February 1, 2025 - February 28, 2025138,203$180.89 138,203$50,000 March 1, 2025 - March 31, 2025304,446$164.23 304,446$— Total442,649442,649

(1) On August 6, 2024, we announced that our Board of Directors authorized the repurchase of up to $150.0 million of our outstanding shares of common stock from time to time through open market transactions, privately negotiated transactions, tender offers, or other means. We are not obligated to repurchase any specific number of shares and the program may be modified, suspended, or discontinued at any time. The share repurchase program was set to expire on August 5, 2026, subject to the earlier termination or extension by the Board, in its sole discretion and without prior notice. As of March 31, 2025, no amount remained available for future repurchases under the share repurchase program.

Item 3.    Defaults Upon Senior Securities.

None.

Item 4.    Mine Safety Disclosures.

Not applicable.

Item 5.    Other Information.

(a)  None.

(b)  None.

40

Table of Contents

(c)  Adoption or Termination of Trading Arrangements by Directors and Executive Officers

There were no "Rule 10b5-1 trading arrangements" or "non-Rule 10b5-1 trading arrangements," as each term is defined in Item 408(a) of Regulation S-K, adopted, modified or terminated by the Company’s directors or "officers" (as defined in Rule 16a-1(f) of the Exchange Act) during the three months ended March 31, 2025.

41